SCHEMBL2946382

SCHEMBL2946382

COc1ccc(CCO)c([N+](=O)[O-])c1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
SMN1; SMN2 Q16637 5/20 0.50
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
MAPK1 P28482 3/20 0.50
LMNA P02545 2/20 0.50
MAPT P10636 5/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
KDM4E B2RXH2 1/20 0.47
CYP2D6 P10635 1/20 0.47
RECQL P46063 1/20 0.46
AKR1C3 P42330 2/20 0.46
AKR1C2 P52895 2/20 0.46
MAOA P21397 1/20 0.45
MAOB P27338 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3582642 0.91 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2NPC1RAB9AMAPK1
SCHEMBL7649455 0.89 PTPN1 (0.47) ALDH1A1SMN1; SMN2NPC1RAB9AMAPK1
SCHEMBL5219494 0.89 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2NPC1RAB9AMAPK1
SCHEMBL14188965 0.86 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2NPC1RAB9AMAPK1
SCHEMBL5220816 0.85 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2NPC1RAB9AMAPK1
SCHEMBL3823448 0.85 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2NPC1RAB9AMAPK1
SCHEMBL5224397 0.84 TAAR1 (0.54) ALDH1A1SMN1; SMN2NPC1RAB9AMAPK1
SCHEMBL3574940 0.84 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2NPC1RAB9AMAPK1
SCHEMBL3576116 0.84 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2NPC1RAB9AMAPK1
SCHEMBL28712089 0.83 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2NPC1RAB9AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2118076-B1 QUINOXALINE COMPOUNDS AND USE THEREOF MERCK SERONO SA (CH) 2019-09-04 EP disclosed
EP-2118076-B1 QUINOXALINE COMPOUNDS AND USE THEREOF MERCK SERONO SA (CH) 2019-09-04 EP disclosed
US-8614215-B2 Quinoxaline inhibitors of phosphoinositide-3-kinases (PI3Ks) MERCK SERONO SA (CH) 2013-12-24 US disclosed
US-20100137308-A1 Quinoxaline Compounds and Use Thereof MERCK SERONO SA (CH) 2010-06-03 US disclosed
US-20100137308-A1 Quinoxaline Compounds and Use Thereof MERCK SERONO SA (CH) 2010-06-03 US disclosed
US-20100137308-A1 Quinoxaline Compounds and Use Thereof MERCK SERONO SA (CH) 2010-06-03 US disclosed
EP-1765267-B1 INITIAL PHENYLPROPANEDIOL DYE PRODUCTS HENKEL AG & CO KGAA (DE) 2010-01-06 EP disclosed
EP-1754685-B1 Organosol of silica and process for producing the same NISSAN CHEMICAL IND LTD (JP) 2010-01-06 EP disclosed
EP-1765267-B1 INITIAL PHENYLPROPANEDIOL DYE PRODUCTS HENKEL AG & CO KGAA (DE) 2010-01-06 EP disclosed
EP-2118076-A1 QUINOXALINE COMPOUNDS AND USE THEREOF Merck Serono S.A. (CH) 2009-11-18 EP disclosed
US-7560491-B2 Z-stilbenes derivatives and the pharmaceutical composition thereof TAIPEI MEDICAL UNIVERSITY (TW) 2009-07-14 US disclosed
WO-2008101979-A1 QUINOXALINE COMPOUNDS AND USE THEREOF MERCK SERONO S.A. (CH) 2008-08-28 WO disclosed
WO-2008101979-A1 QUINOXALINE COMPOUNDS AND USE THEREOF MERCK SERONO S.A. (CH) 2008-08-28 WO disclosed
US-20080096973-A1 Z-stilbenes derivatives and the pharmaceutical composition thereof TAIPEI MEDICAL UNIVERSITY (TW) 2008-04-24 US disclosed
EP-1765267-A1 INITIAL PHENYLPROPANEDIOL DYE PRODUCTS Henkel Kommanditgesellschaft auf Aktien (DE) 2007-03-28 EP disclosed
EP-1754685-A2 Organosol of silica and process for producing the same Nissan Chemical Industries, Ltd. (JP) 2007-02-21 EP disclosed
US-20070032560-A1 Organosol of silica and process for producing same NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2007-02-08 US disclosed
WO-2006002712-A1 INITIAL PHENYLPROPANEDIOL DYE PRODUCTS HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137308-A1 Quinoxaline Compounds and Use Thereof PFKP, PDXK, PF4 ALDH1A1 577/4885SMN1; SMN2 3366/4885NPC1 4792/4885
US-20080096973-A1 Z-stilbenes derivatives and the pharmaceutical composition thereof CCNB1, ZYX, H1-0 ALDH1A1 924/4885SMN1; SMN2 2954/4885NPC1 353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.